Wheat germ improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease : a randomized, placebo-controlled, double-blind clinical trial
Author
Salehi-Sahlabadi, AmmarKord-Varkaneh, Hamed
Kocaadam-Bozkurt, Betul
Seraj, Shaikh Sanjid
Alavian, Seyed Moayed
Hekmatdoost, Azita
Publication date
2022-11-01Subject
GastroenterologyDiet & nutrition
Diseases & disorders of systemic, metabolic or environmental origin
Metadata
Show full item recordAbstract
Globally, Non-alcoholic fatty liver disease (NAFLD) has a rising prevalence with no definitive pharmacological treatments. The aim of this study was to assess the clinical effects of wheat germ in patients with NAFLD. Fifty participants with NAFLD were randomly allocated to take 40 g wheat germ (n = 25) or placebo (n = 25) in a randomized double-blind clinical trial over 12 weeks. Transient elastography (FibroScan) determined a diagnosis of NAFLD. After 12 weeks of intervention, reduction in serum alanine aminotransferase (p = 0.006) and γ-glutamyltransferase (p = 0.004), total cholesterol (p = 0.018), triglyceride (p = 0.046), and hepatic steatosis (p = 0.043) levels in the wheat germ group was significantly higher compared to the placebo group. Serum TAC levels in wheat germ group patients increased significantly higher than placebo group (p = 0.001). Reduction in serum hs-CRP level in the wheat germ group was significantly higher than in the placebo group (p = 0.031). In conclusion, our study shows that wheat germ consumption may improve total antioxidant capacity, hepatic steatosis, serum total cholesterol and triglyceride levels, alanine aminotransferase (ALT), and Gamma-glutamyl Transferase (GGT) in NAFLD patients. Longitudinal studies with larger sample sizes are needed to confirm biological effects of wheat germ on NAFLD patients.Citation
Salehi-Sahlabadi A, Kord-Varkaneh H, Kocaadam-Bozkurt B, Seraj SS, Alavian SM, Hekmatdoost A. Wheat germ improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo-controlled, double-blind clinical trial. Phytother Res. 2022 Nov;36(11):4201-4209.Type
ArticleDOI
10.1002/ptr.7553PMID
35843540Journal
Phytotherapy ResearchPublisher
Wileyae974a485f413a2113503eed53cd6c53
10.1002/ptr.7553